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Systemic lupus erythematosus (SLE) is an inadequately defined syndrome. Etiology and 
pathogenesis remain largely unknown. SLE is on the other hand a seminal syndrome 
that has challenged immunologists, biologists, genetics, and clinicians to solve its 
nature. The syndrome is characterized by multiple, etiologically unlinked manifestations. 
Unexpectedly, they seem to occur in different stochastically linked clusters, although 
single gene defects may promote a smaller spectrum of symptoms/criteria typical 
for SLE. There is no known inner coherence of parameters (criteria) making up the 
disease. These parameters are, nevertheless, implemented in The American College 
of Rheumatology (ACR) and The Systemic Lupus Collaborating Clinics (SLICC) criteria 
to classify SLE. Still, SLE is an abstraction since the ACR or SLICC criteria allow us to 
define hundreds of different clinical SLE phenotypes. This is a major point of the present 
discussion and uses “The anti-dsDNA antibody” as an example related to the problem-
atic search for biomarkers for SLE. The following discussion will show how problematic 
this is: the disease is defined through non-coherent classification criteria, its complexity 
is recognized and accepted, its pathogenesis is plural and poorly understood. Therapy 
is focused on dominant symptoms or organ manifestations, and not on the syndrome 
itself. From basic scientific evidences, we can add substantial amount of data that are 
not sufficiently considered in clinical medicine, which may change the paradigms linked 
to what “The Anti-DNA antibody” is—and is not—in context of the imperfectly defined 
syndrome SLE.
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introdUCtion
This study represents an open-minded approach to try to understand the nature of the syndrome 
Systemic lupus erythematosus (SLE), how it is defined, and how to comprehend its pathogenesis and 
biomarkers. The core of this approach is that it seems difficult for relevant basic and clinical scientists 
to agree to conformed definitions of the syndrome.
Systemic lupus erythematosus is an historically old disease described already in antiquity. 
The disease is a scientifically challenging (1, 2), problematic (3–6), inspiring (7, 8) and seminal 
(9–11), clinical syndrome (12). The syndrome is real in its existence—although hidden behind 
obstacles, cumbersome for patients and clinicians, and rebellious for scientists. It has inspired 
medical and basic biological scientists that focus on molecular biology, basic immunology, 
immunopathology, clinical science, genetics, and epidemiology. Scientists belonging to all these 
FigUre 1 | Patients classified to have systemic lupus erythematosus (SLE) 
by the The American College of Rheumatology (ACR) classification 
criteria—diversity of the clinical phenotypes. On top of the figure, each of the 
11 ACR criteria is presented symbolically (see table 1 for details on the ACR 
criteria). Five patients are demonstrated. The patients share some criteria, but 
diverge with respect to others. This chaotic figure demonstrates that the use 
of criteria is dubious to investigate pathogenesis of the syndrome and to 
search for biomarkers to characterize the syndrome SLE. How can we 
determine common features or biomarkers, when SLE presents so many 
different phenotypes? The patients in this figure are fictive but they reflect 
problems with the ACR in real life.
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disciplines attempt to describe the nature of the syndrome 
SLE but also of individual parameters that constitute criteria 
characterizing the syndrome.
From a wider perspective, studies of anti-dsDNA antibodies 
in SLE have significantly enriched our knowledge about more 
general aspects of the immune system itself. For example, stud-
ies of SLE have promoted a better insight into how the immune 
system controls discrimination between anti-self and anti-non-
self responses. This includes the role of the innate immune 
system in autoimmunity (13–16), the regulation of B  cell and 
T  cell tolerance and deletion (17–19) and receptor editing in 
B  cells (20–24). Yet, the nature and origin of the anti-dsDNA 
antibody itself remain largely enigmatic. We are today not able 
to explain why these antibodies appear in something called SLE. 
On the other hand, problems to define SLE has been a concern 
for empirical and system sciences (25) and has been applied to 
nearby all aspects of the disease (7–9, 26–39).
Systemic lupus erythematosus and its biomarkers have been 
and are still investigated by an interdisciplinary scientific field 
that combine elements from empirical, basic, and clinical sci-
ences. Historical descriptions represent an origin for empirical 
arguments to describe SLE as a serious disease with cutaneous 
manifestations (40–43). Herbernus of Tours (916 AD) was among 
the first to use the term “lupus” to characterize this disease [see 
Ref. (43)]. Further descriptions were in the nearer past expanded 
by the pioneering studies of Osler and Kaposi who extended our 
insight into the disseminated nature of lupus erythematosus; the 
involvement of other organs than the skin [see, e.g., Ref. (40, 44)].
The different empirical, clinical and experimental approaches 
to understand what SLE is, does not imply that individual aspects 
are implemented in systemic multidisciplinary approaches. 
This statement is formulated simply because results from basic 
sciences relevant for SLE are only halfheartedly implemented 
in clinical contexts. This is discussed in detail subsequently 
with a focus on what SLE and “The anti-dsDNA antibody” 
are—and what they are not. In my opinion, there is a lack of 
critical cross-talks between the different fields of science that 
are applied to, or relevant for SLE. Many approaches deals with 
cohort studies based on classification criteria [see, e.g., Ref. 
(33, 45–47)]. Per definition, patients that fulfill a minimum of 
classification criteria are implemented in a cohort. This means 
that the patients compared to each other are phenotypically 
different (see Figure 1 for principle problems). This is a prob-
lematic situation.
Without implementing principles evolving from system analy-
ses, which mean to unify interdisciplinary fields that attempt to 
study complex natural (48) or, e.g., medical syndromes (49), we 
may be left with SLE as we know it today, an enigmatic and a 
controversial, unclassified syndrome. Without a systematic 
approach, this will preclude a holistic view on the complexity of 
SLE as a functional or formal unit.
Unfortunately, instead of being concerned with complete 
systems, there is today a clear trend toward studies of SLE by 
individual disciplines unlinked from each other. As a paradox, 
many disciplines are engaged in the search to understand SLE, 
although the different disciplines hardly communicate with 
each other. Thus, we miss an organized approach to prioritize 
a holistic perspective by not taking all aspects of the syndrome 
SLE into account. This can only be achieved by concentrating 
on the interactions between its different elements. System sci-
ence (25, 49) in our context provides a framework in which 
assessment of data generated by experts in different fields 
can be combined, and confronted with each other in order 
to determine what we agree on, what must be done, and what 
the best strategy forward must be. The following discussion is 
an attempt to underscore the need for profound cross-talks 
between scientific disciplines.
deFining sLe: do We MaKe 
siMpLiFiCations By ignoring 
proBLeMs tHat do not Fit into  
tHe syndroMe as an entity?
Contemporary problematic situations have precipitated the 
trivial view that SLE is a multiorgan disease with poor under-
standing of its pathogenesis (2, 9). How can we think of SLE as 
a well-defined syndrome when it presents with hundreds of dif-
ferent phenotypes (defined by combined classification criteria)? 
And how can we search for biomarkers for such a poorly defined 
syndrome? Werner Heisenberg, who was a principal scientist in 
the German nuclear energy project during World War II, and 
a Nobel Prize laureate, formed the following anti-positivistic 
idiom that, I think, can be applied to all kinds of complex scien-
tific problems. This includes also definition and understanding 
of syndromes like SLE: “The positivists have a simple solution: 
the world must be divided into that which we can say clearly 
and the rest, which we had better pass over in silence. But can 
anyone conceive of a more pointless philosophy, seeing that what 
we can say clearly amounts to next to nothing? If we omitted 
all that is unclear, we would probably be left with completely 
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uninteresting and trivial tautologies” (50). And in this context, it 
is also relevant to cite Ludvik Fleck, a polish microbiologist and 
philosopher. He developed a system of the historical philosophy 
and sociology of science: “For the current state of knowledge 
remains vague when history is not considered, just as history 
remains vague without substantive knowledge of the current 
state” (51). Here, Fleck points to, and reminds us of an important 
element of system science; the implementation of empirical and 
historical knowledge.
The two paradigms cited earlier will function as backdrops 
for the problems discussed subsequently related to try to under-
stand what SLE is. Obviously, there are needs to develop new 
hypotheses and to test them critically. To do so, we then have to 
consider one objective in sight; how do we define a hypothesis 
that may enable us to understand the substance of a syndrome 
like SLE? Here we have to ask the central questions: When are 
data proving something beyond subjective interpretations and 
simplifications, and when do we accept tautologies in order 
to simplify our research and paradigms related to SLE? These 
questions are closely associated with the term hypothesis. What 
is a hypothesis, and what purpose will the hypothesis serve; An 
approach to search for truth (the ideal context)? Or to confirm 
contemporary or historically simplified models (the historical or 
subjective context)?
tHe syndroMe sLe: HistoriCaL  
and ConteMporary ConteXts
Systemic lupus erythematosus has been studied intensively since 
the last century (since 1942, about 65,000 SLE-related articles 
appear on PubMed with the search term “systemic lupus erythe-
matosus”). This enormous amount of data and paradigms has 
not provided us with profound consensus on its nature, etiology 
or pathophysiology [see, e.g., Ref. (52, 53)]. Therefore, unclear 
or contradicting data and results in the past force many of us 
to choose solutions as if they are real although they are based 
on tautologies that may simplify our interpretations—leaving 
its significant historical context in silence (40–43). Thus, it may 
still be difficult to define SLE, as it was in historical, and yet in 
contemporary times. It seems that in antiquity, the disease was 
characterized by serious cutaneous affections while in modern 
times, more and more parameters and criteria are added to the 
list making up the SLE phenotypes. This makes it difficult to 
comprehend the nature of the disease. Here, I will discuss what we 
understand of SLE in terms of its wide definition as a syndrome, 
and if it is a possible task to use such a definition to determine 
biomarkers that characterize it, or point to it.
sLe: a MULti-organ disease or  
a disease LinKing anti-dsdna 
antiBodies and eXposed CHroMatin 
to nepHritis and derMatitis?
Systemic lupus erythematosus is described as a multiorgan, 
though mysterious disease (2, 5, 6, 9, 54). The different organ 
and laboratory manifestations are confusing since they have no 
inner pathogenic coherence, but can appear in a non-concurrent 
way. Still it is defined as a syndrome. Then, how can we think of 
SLE as a well-defined syndrome when it presents with quite dif-
ferent phenotypes [see, e.g., Ref. (55)], and how can we search 
for biomarkers in such a diffuse and non-stringent situation? 
We do not see radical solutions in the near future as to how to 
explain its nature. Rather, we make simplifications, worryingly 
in line with what Heisenberg stated, in trying to understand 
the disease, and to find its biomarkers. Today we classify SLE 
by sets of criteria, like The American College of Rheumatology 
(ACR) (6) and The Systemic Lupus Collaborating Clinics 
(SLICC) (5) criteria, and search for biomarkers in  situations 
where minimum requirements of criteria are fulfilled irrespec-
tive of which of the criteria are present. In this situation, the 
current state of knowledge remains vague, and does not take 
into account descriptions back in antiquity as being a seri-
ous cutaneous disease probably involving the kidneys as the 
malignant element. This is deduced from the fact that lupus-
associated kidney and skin affections may have a common or 
similar pathogenic origin(s) (7, 34, 56, 57). The same problems 
relate to treatment; we classify a disease phenotypically as a 
syndrome, but we treat the most serious organ manifestations, 
not the syndrome as a whole [see a discussion in Ref. (58)]. Are 
we in fact disseminating the core of the classical disease into 
a myriad of parameters, biomarkers, symptoms and statistics 
(manuscript in progress)? Regardless, it seems that the clas-
sification systems for SLE are established, and used in diverse 
contexts; diagnostics, search for biomarkers, but also for single 
manifestations, and for therapeutics. There are obvious needs 
to develop new hypotheses to describe SLE!
For example, one approach would be to analyze expression 
levels of factors indispensable for chromatin metabolism in vivo. 
Recently, a familiar form of SLE was described. This was linked 
to a null mutation of the gene that encodes the secreted deoxy-
ribonuclease DNase 1L3 (59). Sisirak et al. nicely confirmed the 
link between experimental DNase 1L3 deficiency in mice and a 
consequent autoimmunity to dsDNA and nephritis (60). Thus, 
the clinical version of the DNase 1L3 deficiency (59) is directly 
copied by the DNase 1L3 deficiency in experimental mice. This 
is an important approach to describe functional defects leading 
to pathogenic autoimmunity caused by single gene defects. More 
such murine models are expected to appear in the near future 
where deficiencies of single genes that appear central for chroma-
tin metabolism may result in a lupus-like phenotype. If, like in the 
DNase 1L3 deficient mice, the clinical phenotype is characterized 
by anti-dsDNA antibodies and nephritis, this would give a hint 
to the need for re-classification of the human SLE into a “hot” 
SLE with an anti-dsDNA-antibody-driven chromatin-mediated 
nephritis phenotype. This would leave non-nephritis/non derma-
titis behind as lupus phenotypes. Such studies are awaited.
HoW do We deVeLop testaBLe 
HypotHeses aiMed to desCriBe sLe?
Kuhn (61) argued that a “paradigm determines the kinds of 
experiments scientists perform, the types of questions they 
taBLe 2 | The Systemic Lupus International Collaborating Clinics (SLICC) 
classification criteria for Systemic lupus erythematosusa (5).
CLiniCaL Criteria
acute cutaneous lupus or subacute cutaneous lupus
•	 acute cutaneous lupus: lupus malar rash (do not count if malar  
discoid), bullous lupus, toxic epidermal necrolysis variant of SLE, 
maculopapular lupus rash, photosensitive lupus rash (in the absence  
of dermatomyositis)
•	 subacute cutaneous lupus: nonindurated psoriaform and/or annular 
polycyclic lesions that resolve without scarring, although occasionally with 
postinflammatory dyspigmentation or telangiectasias
Chronic cutaneous lupus
•	 Classic discoid rash localized (above the neck) or generalized (above and 
below the neck), hypertrophic (verrucous) lupus, lupus panniculitis (profundus), 
mucosal lupus, lupus erythematosus tumidus, chillblains lupus, discoid lupus/
lichen planus overlap
oral ulcers or nasal ulcers
Oral: palate, buccal, tongue
Nasal ulcers
In the absence of other causes, such as vasculitis, Behcet’s disease, infection 
(herpesvirus), inflammatory bowel disease, reactive arthritis, and acidic foods
nonscarring alopecia
Diffuse thinning or hair fragility with visible broken hairs, in the absence of 
other causes such as alopecia areata, drugs, iron deficiency, and androgenic 
alopecia
synovitis involving 2 or more joints
  Characterized by swelling or effusion
  OR tenderness in 2 or more joints and at least 30 min of morning stiffness
serositis
  Typical pleurisy for more than 1 day OR pleural effusions OR pleural rub
  Typical pericardial pain (pain with recumbency improved by sitting forward) for 
more than 1 day OR pericardial effusion OR pericardial rub OR pericarditis by 
electrocardiography
  In the absence of other causes, such as infection, uremia, and Dressler’s 
pericarditis
renal
  Urine protein–to-creatinine ratio (or 24-h urine protein) representing 500 mg 
protein/24 h OR red blood cell casts
neurologic
  Seizures, psychosis, mononeuritis multiplex (in the absence of other known 
causes such as primary vasculitis), myelitis, peripheral or cranial neuropathy  
(in the absence of other known causes such as primary vasculitis, infection, 
and diabetes mellitus), acute confusional state (in the absence of other  
causes, including toxic/metabolic, uremia, drugs)
HeMoLytiC aneMia
Leukopenia (<4,000/mm3) or lymphopenia (<1,000/mm3)
  Leukopenia at least once: In the absence of other known causes such  
as Felty’s syndrome, drugs, and portal hypertension
  Lymphopenia at least once: in the absence of other known causes such as 
corticosteroids, drugs, and infection
thrombocytopenia (<100,000/mm3)
  At least once in the absence of other known causes such as drugs, portal 
hypertension, and thrombotic thrombocytopenic purpura
taBLe 1 | 1997 American College of Rheumatology SLE Classification  
Criteriaa (6).
•	Malar rash: butterfly shaped rash across cheeks and nose
•	Discoid (skin) rash: raised red patches
•	Photosensitivity: skin rash as result of unusual reaction to sunlight
•	Mouth or nose ulcers: usually painless
•	Arthritis (non-erosive) in two or more joints, along with tenderness, swelling, 
or effusion. With non-erosive arthritis, the bones around joints don’t get 
destroyed
•	Cardio-pulmonary involvement: inflammation of the lining around the heart 
(pericarditis) and/or lungs (pleuritis)
•	Neurologic disorder: seizures and/or psychosis
•	Renal (kidney) disorder: excessive protein in the urine, or cellular casts in the 
urine
•	Hematologic (blood) disorder: hemolytic anemia, low white blood cell count,  
or low platelet count
•	 Immunologic disorder: antibodies to double stranded DNA, antibodies to Sm, 
or antibodies to cardiolipin
•	Antinuclear antibodies (ANAs): a positive test in the absence of drugs known 
to induce it
aRequirements: Any combination of four or more of 11 criteria, well documented at any 
time during a patient’s history, makes it likely that the patient has SLE (specificity and 
sensitivity are 95 and 75%, respectively). (Continued )
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ask, and the problems they consider important” [cited in Ref. 
(62)]. Thus, according to Kuhn, a paradigm may form the bases 
for different hypotheses. Unfortunately, these may promote 
evolution of incommensurable models to explain the nature 
of the disease or the study-object. This can be anticipated as 
far as different hypotheses raised to solve a problem release 
different experimental models that may result in divergent 
interpretations, simply because different hypotheses are tested 
by different analytical approaches. These yield different ana-
lytical results and consequently, different models may appear 
(see subsequently for details). On the other hand, a hypothesis 
is formed to describe a process that may be real (as relevant 
for SLE), or to describe a phenomenon that lacks scientific 
evidence for its very existence, like the scientific history of 
the assumption and subsequent prove for the existence of the 
Higgs boson (63). In fact, the history of SLE is paralleling the 
history of the Higgs boson—do we lack formal evidence for the 
existence of the syndrome called SLE, or is SLE still formally 
an abstraction?
In a biological context, rather than in, e.g., theological or 
philosophical contexts, it is required that we can test a hypoth-
esis by scientific methods that materialize its real biological and 
explainable existence. A critical hypothesis is therefore the basis 
to help us solve complicated system-related biological aberrations 
like those encountered in SLE.
One fundamental hypothesis could be formulated with the 
aim to study why manifestations like the classification criteria 
in SLE appear in various clusters, like criteria in the ACR 
(Table 1) and SLICC (Table 2) classification systems do. This 
may result in one of two possible answers; there is no causal 
or biological link between them; or the clusters are based on 
biological processes that form a causal reason for this linkage. 
We are far from knowing the truth about SLE, its nature, and its 
heterogenic phenotypes.
immunologic criteria
 (1) ANA level above laboratory reference range
 (2) Anti-dsDNA antibody level above laboratory reference range  
(or 2-fold the reference range if tested by ELISA)
 (3) Anti-Sm: presence of antibody to Sm nuclear antigen
 (4) Antiphospholipid antibody positivity, as determined by
  Positive test for lupus anticoagulant
  False-positive test result for rapid plasma reagin
  Medium- or high-titer anticardiolipin antibody level (IgA, IgG, or IgM)
  Positive test result for anti–2-glycoprotein I (IgA, IgG, or IgM)
 (5) Low complement (C3, C4, or CH50)
 (6) Direct Coombs’ test (in the absence of hemolytic anemia)
aRequirements: ≥4 criteria (at least 1 clinical and 1 laboratory criteria) or biopsyproven 
lupus nephritis with positive ANA or anti-DNA.
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tHe CUrrent deFinition oF tHe 
syndroMe sLe and proBLeMs 
LinKed to it
Systemic lupus erythematosus is a syndrome without a clear 
definition of what it is, and it is unclear whether the use of the 
term syndrome should at all be used in the context of SLE. The 
word syndrome descends from the Greek word σύνδρομον, 
that concisely translate into the word “concurrence” in the 
sense of the simultaneous occurrence of symptoms, events or 
parameters that are timely appearing together through a com-
mon etiology or cause (64). This strict definition of a syndrome 
as a condition with simultaneously appearing events is not 
implemented when we discuss SLE as a syndrome. In fact, the 
proposed ACR SLE classification is based on 11 criteria. For 
the purpose of identifying patients in clinical studies, a person 
shall be said to have SLE if any 4 or more of the 11 criteria 
are present, serially or simultaneously, during any interval of 
observations (Table 1). Thus, the manifestations do not have to 
appear timely together, they may appear also in an accumulated 
fashion one by one, and then later make up a syndrome that 
fulfill a term analogous to the idiom syndrome [see, e.g., Ref. 
(6) and discussion in Ref. (1)]. But this is not harmonizing 
with the classical use of the term “syndrome” (=concurrence). 
We are therefore facing two principally different problems: (i) 
the definition of the syndrome SLE and (ii) its lack of a unifying 
or inciting pathophysiological explanation. So we have to make 
a distinction between a disease with secondary manifestations, 
and a syndrome with (non-) concurrent manifestations that are 
linked in a yet not understood way—if biologically linked at 
all. This may be further problematized by the following percep-
tions using anti-dsDNA antibodies as biomarkers regarded as 
specific for SLE.
Systemic lupus erythematosus is per definition composed 
of divergent organ manifestations and laboratory aberrancies 
This may open for a heterogenic population of SLE patients 
included in cohort studies [see, e.g., Ref. (5, 9, 11, 22, 53)]. 
There is no common denominator for the large varieties of 
this disease’s phenotypes (see the principle Figure 1). In ACR 
criteria (Table 1), 4 out of these 11 criteria must be fulfilled to 
classify a disease as SLE. This means, by random combinations 
of 4/11 criteria, we have to accept that SLE by these criteria 
may theoretically present 330 different clinical phenotypes! The 
more recent SLICC SLE classification system (Table 2) has not 
helped us here. Therefore, SLE has many phenotypes that by 
reciprocal comparisons are quite different, is characterized by 
different distinct organ/laboratory manifestations, and present 
quite different clinical pictures. How then can we search for 
biomarkers correlating with the syndrome SLE as it is defined 
today?
tHe anti-dsdna antiBody as 
BioMarKer in sLe: poor deFinition 
oF tHe partners
Antibodies to dsDNA are claimed to be associated with, and 
to serve as biomarkers for SLE (8, 65, 66). However, “The anti-
dsDNA antibody” is not an unambiguous parameter (7, 8, 52), 
and SLE is not an unambiguously defined disease. How then 
can “The anti-dsDNA antibody” serve as a biomarker for the 
syndrome SLE?
Theories, models or algorithms are defined as incommensu-
rable if they derive from contrasting experimental or theoretical 
contexts although aimed to describe the very same problem. 
Their basic parameters may not be sufficient to permit scientists 
to directly compare the models or to cite empirical evidence 
favoring one theory over another (51). Incommensurable mod-
els inevitably promote scientists to be confused about terms, 
contexts and consequences, as is the case for SLE. With respect 
to SLE and to, e.g., lupus nephritis, divergent pathophysiological 
models may preclude consensus on pathogenesis [see, e.g., Ref. 
(61)]. To harmonize models that are divergent in order to reach 
de facto consensus may be a sine qua non in development of 
causal therapies.
In this context, we have to accept that facts simply are the 
case, subsequently interpreted as that—objective, physically 
distinguishable traced cases. They are discovered through 
proper observations from experimentally testable realities. Fleck 
would here submit that facts are invented or interpreted—not 
discovered. One can add to the problem of “conclusive facts or 
data” the following paradox in serious science: If experiments are 
performed to prove a hypothesis, then data can be interpreted 
as if the model simply reflects the exact fact. A problem in this 
context is the traditional impediment to generate experiments 
aimed to actively prove the opposite; namely that the hypothesis 
is wrong. This situation envisages how the same study-object 
promotes incommensurable models because those that will prove 
the validity of a hypothesis describes a model that differs from 
alternative models that are based on experiments instigated by 
other hypotheses.
How then can we succeed when the efforts are aimed to explain 
a syndrome with so many clinical phenotypes, and how can we 
search for biomarkers like “The anti-dsDNA antibody” in this 
landscape? Do we here see the contour of serious problems linked 
to cohort studies were the study-objects (here SLE patients) are 
classified by internationally well-accepted criteria (like ACR or 
SLICC)? In this context, it is clear that the cohort is basically 
FigUre 2 | Theoretical anti-dsDNA antibody profiles in context of systemic 
lupus erythematosus (SLE) classification criteria. The American College of 
Rheumatology (ACR) and SLICC SLE classification criteria include 
anti-dsDNA antibodies as a criterium. As a criterium the antibodies are poorly 
defined. For example, a short-lived stimulus by an infectious agent may 
induce transient antibodies at low titers (a). If the infectious stimulus prevails, 
the anti-dsDNA antibody may prevail at low titers, even though above the 
assay cutoff level (B). The anti-dsDNA antibody production in (C) is transient, 
although at high titers, as a consequence of a strong, transient stimulus 
either of autologous or, e.g., infectious origin. In (d), the immune response is 
characterized by sustained production of anti-dsDNA antibodies at high to 
very high titers. The red parts of each profile represent autoantibody levels 
above the antibody cut-off levels as defined by ACR or SLICC criteria. The 
curves are fictive and constructed empirically in order to demonstrate the 
variability of anti-dsDNA antibody profiles, all of which fulfill requirements in 
the ACR and SLICC classification criteria for SLE. See text for details.
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heterologous and not suitable for causal and penetrating studies 
of SLE. Can a search for biomarkers help us here?
sLe and anti-dsdna antiBodies: do 
tHe Latter reFLeCt tHe First?
In order to discuss the nature and role of anti-dsDNA 
antibodies as biomarkers or pathogenic factors in clinical 
medicine, it may be wise to shortly describe the history of 
the antibody.
anti-dsdna antiBodies—a sHort 
History
In the history of immunity, hardly any naturally produced auto-
antibody has attracted so many basic- and clinical-oriented 
scientists as the antibody against mammalian B helical DNA. 
During the last 40 years, more than 2,200 articles are published 
(PubMed search term: anti-dsDNA antibodies). The anti-DNA 
antibodies were first described in 1938 and 1939 in bacterial 
infectious contexts (67–69), and further studied and their 
presence confirmed 15  years later (70). In 1957, anti-DNA 
antibodies were described in a strict autoimmune context; in 
SLE (71–74).
In 2015 (7) and in 2016 (8), manuscripts were published with 
apparently opposite views regarding the clinical and biological 
impact of anti-dsDNA antibodies. In the first, their impact as 
biomarkers for SLE were questioned and critically discussed 
(7, 66). In the other, they were after a sound and critical survey 
of the literature defined as quintessential biomarkers for SLE (8). 
The clear statement denoting anti-dsDNA antibodies as strong 
biomarkers for SLE (8) is, however, difficult to comprehend in 
light of the definition of SLE, its many different phenotypes, and 
the wide range of biological properties and unique specificities of 
“The anti-DNA antibody” [a term used in the classification cri-
teria for SLE (5, 6)]. On the other hand, the view that hesitates to 
accept anti-dsDNA antibodies as biomarkers for SLE (7) is hard 
to understand in light of the enormous efforts and data to prove 
exactly that. The ACR criterion 10 says: “Anti-DNA: antibody to 
native DNA in abnormal titer” (6), while in the SLICC criteria 
anti-dsDNA antibodies is described as valid if the Anti-dsDNA 
antibody level is above laboratory reference range (or twofold the 
reference range if tested by ELISA) (5).
There are several practical and theoretical tribulations 
linked to these definitions. The anti-dsDNA antibody is a poorly 
defined term that does not take into account that anti-dsDNA 
antibodies comprise a large array of unique specificities, quite 
different and unique origins, some based on spontaneous auto-
immunity, some linked to cancers, others linked to external 
factors like drugs and infections. Furthermore, according to 
the classification criteria, the antibody may be weak (although 
above a threshold value), transient, sustained at high or low 
titers in different patients suffering from, e.g., SLE, cancers or 
infectious diseases (see the principles in Figure 2), and they 
may differ in avidity and cross-reactivity as long as they bind 
dsDNA. Still, they are accepted as a SLE classification criterion. 
This will be discussed in detail subsequently.
anti-dsdna antiBodies—statUs  
oF tHeir deFinition and CLiniCaL 
iMpaCt
Dogmas say that anti-dsDNA antibodies are real—they exist 
(although they may be induced by non-dsDNA immunogens), 
they occur in SLE, and they represent a classification criterion 
for SLE. These dogmas can, however, be analyzed in light of 
the philosophical view cited earlier by Heisenberg and thus be 
transformed and applied to our present problem. Our way to 
describe SLE practically represents a brave circumvention of 
problems or facts that do not fit into the simple solution (in the 
context expressed by the anti-positivists); namely that “the anti-
dsDNA antibody” is not linked to SLE. Anti-dsDNA antibodies 
are detected in many other conditions, but the antibody may still 
be a pathogenic factor in SLE, provided DNA is exposed in vivo 
(7, 8, 66). The antibodies may recognize all nucleic acid structures 
presented in the chromatin, both in its resting state and in struc-
tures related to activation of chromatin (75, 76). These structures 
include DNA sequences, ssDNA, dsDNA, B dsDNA, Z dsDNA, 
elongated, or bent dsDNA [(77–82), reviewed in Ref. (7)]. It has 
never been determined if the manifold of anti-dsDNA antibodies 
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are all pathogenic. This problem has a strong impact on choice 
of DNA used as targets in clinical assays if we know which of the 
structures are important in a clinical context.
Already after the 1938/1939 and the 1957 observations on 
anti-dsDNA antibodies, a growing conflict ascended when 
scientists tried to describe the origins of the antibodies [infec-
tious immunity versus true autoimmunity see, e.g., Ref. (7, 27) 
for discussions] and their clinical impact [in diagnostic and 
pathogenic contexts (5, 8, 54, 66)]. In particular, the antibodies 
have after 1957 been surrounded by myths, conflicts and enigmas 
up to contemporary times, due to the problem to determine (i) 
their biological origin—chromatin/dsDNA or crossreactive non-
dsDNA structures; (ii) if they represent one antibody population 
or a heterogenic mixture of DNA-reactive antibodies with dif-
ferent precise specificities for unique DNA structures, and (iii) 
if targeted and inciting DNA structures originate from different 
species like viruses, prokaryotes, or eukaryotes. These aspects will 
be discussed in detail subsequently.
In this discussion, we need to challenge the canonical impact 
of “The anti-dsDNA antibody” as biomarker for the autoim-
mune syndrome SLE. “The anti-dsDNA antibody” exists and is 
described in context of bacterial and viral infections (27, 67– 
69, 83–93), different cancer forms (94–107) and in autoimmune 
syndromes like autoimmune hepatitis (108), Sjøgren syndrome 
(109), SLE (33), or primary antiphospholipid syndrome (110) and 
other disorders. The term “anti-dsDNA antibody” must therefore 
be changed to “anti-dsDNA antibodies,” also in light of the dif-
ferent DNA structure-specificities that characterize the diverse 
anti-dsDNA antibodies. In a blinded study, it was found that 
assessment of anti-dsDNA antibodies by different assays was not 
reliable as a diagnostic tool in unselected patients with rheumatic 
symptoms (111, 112). Furthermore, anti-dsDNA antibodies had 
low positive predictive value for the SLE diagnosis [discussed in 
Ref. (52)]. For non-SLE patients, anti-dsDNA antibodies seemed 
to represent a poor predictor for SLE within an observation 
period of 5 years (111, 112).
Thus, as mentioned previously it can be stated that the ability 
to produce anti-dsDNA antibodies is not restricted to SLE. For 
example, normal mice respond to nucleosome-peptide immu-
nization by producing anti-nucleosome antibodies, anti-ssDNA 
and anti-dsDNA antibodies, some of which may have pathogenic 
effects in vivo (4, 83, 86–88, 113–117).
tHe anti-dsdna antiBody—LaCK  
oF ConsensUs strUCtUre For  
dna Used as target antigen  
in CLiniCaL assays
Anti-dsDNA antibody assay principles and nature of the assay 
targets are not recommended or specified in the ACR or SLICC 
criteria. Thus, we have not developed classification criteria for 
anti-dsDNA antibodies used in clinical analyses. We need here 
to define stringent structural criteria for the anti-dsDNA anti-
body assay targets. These must be combined with consensus on 
specific antibody profiles (transient versus persistent, Figure 2) 
and structural specificities (dsDNA, ssDNA, viral, plasmid, or 
elongated or bent mammalian dsDNA). Notably, the nature of 
target nucleic acids used in assays differ from laboratory to labora-
tory, which may result in detection of quite different nucleic acid 
structures and hence of different antibody specificities, unknown 
origins, or of different pathogenic impacts. For example, some of 
these antibodies are easy to induce experimentally, while some 
derive from processes yet not understood, as in SLE (7, 80, 
118, 119), or exert differences in specificities for, e.g., B dsDNA 
versus Z dsDNA (80). It is not even settled whether autologous or 
heterologous instigating stimuli impose antibodies with similar 
or identical specificities as to those produced in SLE, although 
experimental data may indicate that [(87, 115, 117, 120, 121), 
reviewed in Ref. (7, 8)].
anti-dsdna antiBodies—origins  
and CLiniCaL ConteXts in a 
Broader sense
Anti-DNA antibodies can, as stated earlier be induced in differ-
ent contexts and clinical situations. Some of the antibodies are 
clinical epiphenomena (e.g., due to low avidity, or because the 
targets for the antibodies are hidden or not exposed in  vivo). 
Others may serve as quasi biomarker for SLE, but occur in 
many other disorders as well (7, 52, 66, 122). Some may serve 
as pathogenic factors mostly in kidneys (3, 7, 57, 123–128) or in 
skin (56, 123, 129).
In the next section, models and evidences will be presented 
and discussed that may make distance to the idiom that anti-
dsDNA antibodies are biomarkers for SLE. As a devil’s advocate1, 
I will turn this statement up-side-down and argue that SLE is 
not consistently defined, and anti-dsDNA antibodies are not 
confined to SLE, but to many quite different conditions. Some 
of these conditions will be described subsequently and serve 
to demonstrate that anti-dsDNA antibodies are not unique for 
SLE. The main statement is that the anti-dsDNA antibodies are 
produced transiently or permanently, and all are accepted as 
ACR/SLICC criteria (Figure 2). The antibodies may be specific 
for different species DNA (e.g., from mammalia, fungi, bacteria, 
and viruses), and are produced in context of diverse malignan-
cies. They present surprisingly different specificities for shapes 
exposed by the whole universe of dsDNA structures as they 
appear in relaxed and activated chromatin (7, 75). Still they are 
accepted as criteria for SLE!
BaCteriaL inFeCtioUs-reLated 
iMMUne responses to nUCLeiC 
aCids—tHe Hapten-Carrier ModeL
Antibodies to nuclei acids have been known for 80  years in 
bacterial infectious contexts, while known for 60  years in 
1 Devil´s advocate (originally a catholic paradigm): someone who pretends, in an 
argument or discussion, to be against an idea or plan that a lot of people sup-
port, in order to make people discuss and consider it in more detail (Cambridge 
Dictionary).
FigUre 3 | Cognate interaction of DNA-specific B cells and bacterial-derived 
peptide-specific T cells. This example describes a classical hapten-carrier-like 
model to explain production of anti-dsDNA antibodies in non-SLE (left panel) 
and in SLE conditions (right panel). In this model, chromatin-associated 
dsDNA functions as a non-immunogenic hapten that is recognized by the 
B cell antigen receptor, while heterologous, bacterial DNA-binding 
protein-derived peptides function as carrier proteins that activate peptide-
specific T helper cells. In this scenario, T cell tolerance for nucleosomes is 
maintained intact, and the immune response is transient and is limited to the 
duration of the bacterial infection. According to Pisetsky et al. (83, 135), the 
immune response is dichotomous in the sense that in a normal immunogenic 
context, the antibodies recognize bacterial DNA (left part of the panel), while 
in an autoimmune (SLE-like) context antibodies are also produced that 
recognize mammalian dsDNA (right part of the panel). These processes may 
be operational in vivo in experimental and native contexts.
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an autoimmune context. Thus, anti-DNA antibodies were 
described distinctively earlier than their discovery in SLE in 
1957. These findings implied that DNA stimulated the immune 
system during bacterial infections, and in context of SLE. Still, 
we do not know the molecular and cellular processes that 
promote the production of the antibodies in SLE, while we 
understand more about mechanisms that impose anti-DNA 
antibodies in context of infections [discussed in Ref. (7, 8, 
27, 130)]. The different infectious models provide central 
concepts to describe autoimmunity to dsDNA, and to non-
dsDNA proteins contained within chromatin (for details, see 
subsequently).
The infectious paradigm to explain incitement of anti-
dsDNA autoimmunity, changed dramatically in mid 1990s by 
the pioneering and important studies of Pisetsky et al. (27, 83, 
85). They successfully induced immune responses to bacterial, 
but also to autologous mammalian dsDNA. They did so by 
coupling bacterial DNA to the immunogenic carrier molecule 
methylated bovine serum albumin (mBSA), often used to induce 
antibodies to different natural and synthetic DNA structures 
[see, e.g., Ref. (77, 78, 131–133), reviewed in Ref. (7)]. This 
approach was in general known as the “hapten-carrier” para-
digm. It says that nucleic acids or chromatin fragments serve as 
a B cell-specific non-immunogenic hapten-like structure. The 
carrier protein was immunogenic and presented to cognate 
T helper cells by the nucleic acid-specific B cells [(85, 87, 88, 
131, 134), see examples of hapten-carrier models in Figures 3 
and 4]. This type of cognate B cell and T cell interaction resulted 
in humoral responses against DNA structures recognized by 
the B cell.
Notably, bacterial DNA, in contrast to mammalian DNA, 
contains immune-stimulatory structures characterized by 
CpG motifs or immune-stimulatory sequences [ISS, dis-
cussed in Ref. (136, 137)]. These are characterized by the 
presence of two 5′ purines, an un-methylated CpG motif and 
two 3′ pyrimidines (138). The presence of a CpG motif in 
bacterial DNA stimulates the secretion of proinflammatory 
cytokines and therefore functions similarly to an adjuvant 
(136, 139, 140).
Pisetsky et al. observed that immune responses to bacterial 
DNA–mBSA complexes presented a remarkable dichotomy 
pattern. While responses to bacterial DNA in normal, non-
autoimmune mice were dominated by antibodies specific for 
bacterial DNA (Figure 3, left panel) (141), the same immuniza-
tion regime in young lupus-prone mice resulted in accelerated 
appearance of antibodies against mammalian dsDNA—i.e., for 
autologous DNA typical for the enigmatic antibodies appear-
ing in SLE (Figure  3, right panel) (83, 142). This means that 
bacterial infections may promote production of lupus-like anti-
dsDNA antibodies on certain genetic backgrounds. Since SLE is 
disposed for infections (143–146) the operational mechanism 
to produce anti-dsDNA antibodies in SLE may therefore well be 
linked to the infectivity state of the patients, at least for some 
of them (145, 147). From this, there is no doubt that bacterial 
infections have the potential to promote production of anti-
bacterial and anti-mammalian dsDNA antibodies [discussed 
in Ref. (7, 8)]. Still, the model described by Pisetsky et  al. is 
the most adequate explanation to describe at least initiation 
of immune responses to dsDNA in a natural in vivo situation 
related to SLE.
FigUre 4 | Cognate interaction of DNA-specific B cells and DNA-binding and virus-derived peptide-specific T cells. The figure presents two variants of a classical 
hapten-carrier-like model. In this model, chromatin from virus-infected cells are released in complex with DNA-binding viral proteins (left panel). Cognate interaction 
of mammalian dsDNA-specific B cells and virus peptide-specific T cells result in production of antimammalian dsDNA-specific antibodies. This process may be 
operational in genetically normal individuals (115, 117). In the right panel, the virus-infected cells also release viral mini chromosomes in complex with viral proteins. 
B cells recognize viral DNA, and present processed DNA-bound virus-encoded peptides to non-tolerant T cells. In this situation, antivirus DNA antibodies are 
produced. The antibody profiles depend on the time-line and kinetics of the virus infection. From this, lupus-like anti-dsDNA antibodies may appear in non-lupus 
individuals, thus questioning the validity of pure detection of anti-dsDNA antibodies as a SLE classification criterion.
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Marion et  al. observed and described at the same time 
another infectious-related mechanism that could instigate 
production of anti-dsDNA antibodies. They did the important 
observation that mammalian dsDNA in complex with the 
DNA-binding peptide Fus 1 derived from Tryanozoma cruzii 
had the capacity to induce antibodies to mammalian dsDNA 
(87, 148). Furthermore, they demonstrated that these induced 
antibodies were nephritogenic, as the immunized, normal 
non-autoimmune mice developed a kidney disease that was 
very similar to lupus nephritis. The studies described earlier 
represent significant seminal experiments that have helped 
to understand processes that may explain also spontaneous 
production of lupus-like anti-dsDNA antibodies. These data 
may also demonstrate that anti-mammalian dsDNA antibodies 
is not an integrated part of SLE since they can be observed in 
conditions other than SLE.
VirUs inFeCtioUs-reLated iMMUne 
responses to nUCLeiC aCids—tHe 
Hapten-Carrier ModeL
Viruses have been discussed as pathogenic factors in SLE for 
decennials (88, 149–153). This discussion refers to two possible 
roles of the viruses. One is that viruses may promote autoimmun-
ity during productive infection, where the viral transcriptional 
factor is expressed and bind viral and host cell DNA/chromatin 
(115, 154–156). In dying cells, chromatin-viral transcription fac-
tor complexes are released and presented to the immune system 
in context of a hapten-carrier analog [see, e.g., Ref. (88, 115)]. The 
other role of viruses is linked to sustained productive infections, 
a situation that may promote sustained autoimmunity [discussed 
in Ref. (88, 157)]. Inspired by the Pisetsky observations, we 
FigUre 5 | Induction of anti-dsDNA antibodies by in vivo expression of a 
single viral dsDNA-binding protein. Injection of normal mice with plasmids 
encoding wild type polyomavirus DNA-binding T antigen in context of 
eukaryotic promoters induced production of antibodies to T antigen and 
significant production of antibodies to mammalian dsDNA, histones, and to 
certain transcription factors like TATA-binding protein (TBP) and cAMP-
responsive element-binding protein (CREB). All autologous chromatin-derived 
ligands physically linked to T antigen can therefore be rendered immunogenic 
to autoimmune B cells that present peptides derived from T antigen. 
Therefore, concerted production of autoantibodies specific for chromatin 
antigens, including dsDNA and histones, is not depending on a systemic 
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observed a similar dichotomous response when we immunized 
mice with linearized polyomavirus dsDNA in complex with 
a carrier-protein. Normal mice produced antibodies to viral 
dsDNA (158), while applying the same immunization regime 
on young lupus-prone mice, they produced antibodies to both 
viral and mammalian dsDNA (159, 160); i.e., results that were in 
agreement with the data published by Pisetsky et al. (83, 135, 161).
poLyoMaVirUs t antigen: a natUraL 
Carrier protein For dsdna and 
CHroMatin in an aUtoiMMUne 
ConteXt
Since polyomaviruses obviously had the potential to induce the 
production of anti-dsDNA antibodies in experimental animals, 
this pointed at virus-encoded proteins as potential carrier mol-
ecules rendering DNA immunogenic. Indeed, in the permissive 
host, polyomavirus large T antigen is required for viral tran-
scription and replication, and binds both viral and host DNA/
chromatin (117, 134), and it was shown to be expressed in SLE 
patients (117). Thus, virus-encoded dsDNA-binding proteins 
could represent a non-self DNA-bound protein that served as 
the T cell determinant that could provide help for mammalian 
dsDNA-specific B cells (Figure 4, left part) and for viral dsDNA-
specific B cells (Figure 4, right part) provided they processed and 
presented T antigen derived peptides.
In two experimental systems, these presumptions were 
verified. In one, we demonstrated that injection into normal 
mice with plasmids encoding wild type DNA-binding T antigen 
under control of eukaryotic promoters produced antibodies to T 
antigen. These antibodies were kinetically linked to significant 
production of antibodies to dsDNA, histones, and to certain 
transcription factors like TATA-binding protein and CREB, 
deduced to be produced according to the idea of the model: all 
autologous ligands physically linked to T antigen could theo-
retically be rendered immunogenic provided the presence of a 
(functional) repertoire of autoimmune B cells [see Figure 5 for a 
theoretical model based on experiments and descriptive observa-
tions (115, 117), discussed in Ref. (1)]. In this model, a diversified 
repertoire of chromatin-specific B cells processed and presented 
a single chromatin-bound viral protein. The validity of the model 
was further proven by the following observations. Injection of 
plasmids expressing irrelevant non-DNA-binding proteins like 
luciferase, plasmids containing T antigen sequences but lacking 
a promoter, or plasmids encoding and expressing a truncated 
T antigen without the property to bind DNA did not result in 
such antibodies (115). In a similar experimental system, Dong 
et al. (162) demonstrated that the proto-oncogene p53 can bind 
T antigen. When injecting in vitro formed complexes of p53 and 
T antigen, the mice responded to the immunization regime by 
producing autoantibodies to p53 and to T antigen, thus indicat-
ing that T antigen may render non-immunogenic autoantigens 
immunogenic upon complex formation. in a non-SLE condition. 
In other similar experiments, it has been demonstrated that 
immunization of normal mice with the C-terminal DNA-binding 
domain of the human papillomavirus E2 protein (163), and the 
in  vivo expression of the Epstein–Barr virus nuclear antigen-1 
(EBNA-1) in normal mice (86) both instigated the production of 
anti-dsDNA antibodies.
What have these experiments learned us? The infectious mod-
els are relevant to explain evolution of anti-dsDNA antibodies 
in SLE as well as in non-SLE conditions. Still, true spontaneous 
autoimmunity—i.e., driven by true autoimmune T helper cells—
to dsDNA and chromatin is poorly understood, but the results 
discussed earlier clearly demonstrate that anti-dsDNA antibodies 
is a reflection of immune responses to dsDNA and chromatin 
in many different situations, and they can therefore principally 
not be a biomarker for SLE. Notably, we are today not able to 
distinguish between anti-dsDNA antibodies produced as true 
autoantibodies in SLE from anti-dsDNA antibodies produced in 
other contexts.
MoLeCULar MiMiCry
Molecular mimicry is an alternative approach to study origin 
and impact of anti-dsDNA antibodies. For example, several 
distinct anti-dsDNA antibodies cross-react with non-nucleic 
acid structures like, e.g., phospholipids (164, 165), α-actinin 
(166–168), peptides like DWEYSVWLSN (169), entactin (113), 
the platelet integrin GPIIIa49-66 (170), and others. Which of the 
cross-reacting structures are initiating this dual immune response 
in vivo is not known. This open for the idea that the B cell recogni-
tion of dsDNA is a “by-standing” specificity which in fact has no 
FigUre 6 | A theoretical model to explain peptide-induced anti-dsDNA and 
anti-peptide antibodies. Some peptides have the property to act as inducers 
of anti-dsDNA antibodies. There are problems with this cross-stimulating 
model, since it is not obvious that the peptide-induced immune response will 
affinity maturate toward dsDNA. Rather, somatic hypermutations in the variable 
heavy chain complementary determining regions (VH CDR) may shift the dual 
specificity toward a focused specificity for the peptide. Whether chromatin 
(indicated in the figure) may drive the peptide-induced anti-dsDNA antibody 
further is unlikely from two reasons. For the first, the initial response is 
controlled by peptide-specific, and not by chromatin-specific T cells. Second, 
if chromatin was not involved in early phases of the responses, it is no reason 
to believe it is rendered immunogenic in later phases of the responses.
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meaning for the “real” immune response [see Figure 6, and e.g., 
early discussions in Ref. (93, 164), and also (171, 172)]. In this 
respect, it is of interest to read the manuscript of Wang et al. (173). 
In that review, they highlight the biological roles and structures 
of different reported proteins that mimic DNA. Their analytical 
approach might be used to discover other proteins that have this 
peculiar characteristic.
I do not intend in this study to discuss in depth origin and 
impact of anti-dsDNA antibodies that cross-react with non-DNA 
structures. Whether such antibodies at all should be named 
“anti-dsDNA antibodies” has not reached consensus, not even 
been principally discussed. Since this study concerns about 
how we define SLE, and how we define anti-dsDNA antibod-
ies as biomarkers for SLE, it may be relevant to define three 
intricate difficulties related to molecular mimicry; (i) who are 
the initiators of the dual-specificity antibodies in  vivo, (ii) will 
both specificities prevail, as the affinity maturation of their B cell 
heavy and light chain variable-regions prevail, and (iii) which of 
the structures will in the end be the in situ target for the antibod-
ies. How does this translate into the understanding of avidity in 
context of anti-dsDNA antibodies and SLE? In a situation where 
an immune response is instigated by an antigen mimicking 
dsDNA, the primary humoral immune response will most likely 
produce cross-reactive antibodies. However, secondary immune 
responses instigated by the DNA-mimicking ligand will most 
probably affinity maturate toward that ligand and the antibodies 
may gain higher affinity toward the inducer. At the same time, 
the paired self-specific branch of clones may die out because they 
somatically mutate away for the real immunogen if not the two 
antigens are structurally identical. The whole story is, notably, 
that the immune response is instigate by the non-self antigen that 
engage relevant B cell clones. However, as the self antigens tar-
geted by the crossreactive antibodies are not immunogenic, they 
are assumed to prevail non-immunogenic, simply because there 
is no reason to assume that a cross-reacting antibody may render 
autoantigens immunogenic. Therefore, the autoimmune branch 
of a cross-reaction will not influence on affinity maturation, they 
will turn away from the non-self branch, and they will die out.
I therefore hesitate in this study to discuss origin and impact of 
anti-dsDNA antibodies that cross-react with non-DNA structures. 
In a native situation we have to accept that we cannot say which 
of the cross-reacting antigens are the inducer that may prevail 
the immune response in vivo, and which one may be targeted by 
the antibodies. This is in the end a matter of antibody avidity and 
antigen availability with relevance to ask if anti-dsDNA antibod-
ies in a deeper sense can act as a biomarker for SLE. However, the 
molecular mimicry model for instigating anti-dsDNA antibodies 
definitively show that these antibodies are not strictly linked to 
SLE. Most of the information from immunization experiments, 
and from theoretical and clinical information discussed earlier, 
is in disagreement with the notion that anti-dsDNA antibodies 
are, or can act as biomarkers for SLE. They appear in so many 
non-autoimmune and autoimmune situations.
CLosing reMarKs
Systemic lupus erythematosus is an intriguing and engaging condi-
tion. The present human SLE paradigm evolved from being a skin 
disease in antiquity into a complicated syndrome involving many 
organs and biological processes. Although an object for many dif-
ferent scientific approaches, still SLE presents itself as an enigma 
and an abstraction difficult to comprehend in a physical and 
intellectual context. The studies described earlier provide insight 
deriving from clinical and experimental information. These have 
helped significantly to understand processes linked to production 
of anti-dsDNA antibodies in non-autoimmune and autoimmune 
SLE-like contexts. The data also demonstrate that anti-mamma-
lian dsDNA antibodies are definitively not an integrated part of 
the syndrome SLE. They can be observed in other conditions. SLE 
has been described as a serious skin disease, thereof the antique 
name in association with a clinical morphology bringing the idea 
of a wolf bit, thereby “lupus erythematodes.” In modern medicine, 
this simple comprehensive has been left behind, and modern 
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classification criteria have been introduced. This implies that 
the “lupus erythematodes” has evolved from a serious cutaneous 
disease, and that the seriousness implied nephritis. Nephritis 
was, however, not a major criterion in the antique times. In later 
times, lupus erythematodes has transformed from a strange, 
oligosymptomatic disease into a syndrome with classification 
criteria leaving the modern “SLE” quite different to former times 
disease definition. We have learned much from these paradigm 
shifts, about molecular biology, molecular pathology, clinical 
and epidemiological science, and basic and clinical immunol-
ogy. In the case of our understanding of SLE, I do not think we 
have learnt much. It is stated that “The anti-dsDNA antibody” 
is a classification criterion for SLE. From all described earlier, 
the pure appearance of “The anti-dsDNA antibody” is closer to 
be an epiphenomenon in clinical medicine, rather than to be a 
pathogenic factor or biomarker, which, however indisputably also 
is associated with SLE. One potentially important question raised 
earlier is the following: “SLE and Anti-dsDNA antibodies: Do the 
latter reflect the first?” The answer to this central question is given 
from what is described earlier.
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